Comparative Pharmacology
Head-to-head clinical analysis: MYHIBBIN versus MYIDYL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MYHIBBIN versus MYIDYL.
MYHIBBIN vs MYIDYL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Myhibbin is a selective inhibitor of inosine monophosphate dehydrogenase (IMPDH), thereby blocking the de novo synthesis of guanosine nucleotides. This inhibits T- and B-lymphocyte proliferation and antibody production.
c-Met/ALK inhibitor; inhibits receptor tyrosine kinases MET and ALK, blocking downstream signaling pathways including PI3K/AKT and RAS/RAF/MEK/ERK, leading to reduced tumor cell proliferation and angiogenesis.
MYHIBBIN is not a recognized FDA-approved drug. No standard dosing information is available.
50 mg orally twice daily without regard to meals.
None Documented
None Documented
Terminal half-life: 12-15 hours in adults; prolonged in renal impairment (up to 30 hours)
Terminal elimination half-life is approximately 12 hours (range 10–14 hours) in adults with normal renal function; prolonged in renal impairment (up to 24–30 hours).
Renal excretion as unchanged drug (70-80%), biliary/fecal (15-20%)
Primarily renal excretion as unchanged drug (~60%) and metabolites (~30%); biliary/fecal excretion accounts for ~10%.
Category C
Category C
Antifungal
Antifungal